Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
Ashesh Jani, M.D., said there has been a considerable increase in referred post-prostatectomy patients with lower prostate-specific antigen (PSA) levels, making it increasingly important to have diagnostic tools that can help identify recurrent prostate cancer in this patient population.
In a presentation at the recent American Society for Radiation Oncology (ASTRO) conference, Dr. Jani discussed key research findings from a post-hoc analysis of the phase 3 SPOTLIGHT trial that looked at the use of the positron emission tomography (PET) prostate-specific membrane antigen (PSMA) agent flotufolastat F 18 (Posluma, Blue Earth Diagnostics) for patients with suspected prostate cancer recurrence and PSA levels lower than 1 ng/mL.
In a recent interview, Dr. Jani said he and his colleagues found that use of flotufolastat F 18 detected prostate cancer recurrence in 68 percent of patients with a PSA level less than 1 ng/mL and 64 percent of men with PSA levels lower than 0.5 ng/mL.
“With the advent of molecular imaging and novel radiotracers, we’re able to see the source of PSA at lower PSA levels,” noted Dr. Jani, a professor in the Department of Radiation Oncology at the Emory University School of Medicine and the James C. Kennedy Professor in Prostate Cancer at the Winship Cancer Institute of Emory University.
(Editor’s note: For related content, see “Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer,” “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer” and “Could a New PSMA PET Agent Improve Detection of Distant Metastatic Lesions in Patients with Prostate Cancer?”)
The use of flotufolastat F 18 also led to the detection of extrapelvic lesions in 39 percent of patients with PSAs between 0.5 and 1 ng/mL, and 21 percent of men with PSA levels lower than 0.5 ng/mL, according to Dr. Jani.
“There was significant potential for changing management decisions based on this test,” emphasized Dr. Jani.
(Editor’s note: For related content on prostate cancer imaging, click here.)
For more insights from Dr. Jani, watch the video below.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
